Trial Profile
A Cohort Study of Conversion From Aranesp to NESP for the Treatment of Anemia in Dialysis Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Jan 2022
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- 31 May 2018 Status changed from recruiting to completed.
- 03 Dec 2015 Planned End Date changed from 1 Dec 2016 to 1 May 2017 as reported by ClinicalTrials.gov.
- 03 Dec 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.